CompletedPhase 4

Efficacy of Potassium Sodium Hydrogen Citrate Therapy on Renal Stone Recurrence and/or Residual Fragments After Shockwave Lithotripsy and Percutaneous Nephrolithotomy in Calcium Oxalate Urolithiasis

80 participantsStarted 2005-05

Plain-language summary

Extracorporeal shock wave lithotripsy (ESWL) and Percutaneous nephrolithotomy (PCNL) become the therapy of choice for renal stone. Although providing good results, stone recurrence is usually found as the therapies do not change the underlying metabolic abnormality. Among the metabolic disorders, hypocitraturia is an important risk factor for calcium nephrolithiasis. This study evaluate the preventive effects of potassium sodium citrate on stone recurrence as well as stone growth post ESWL or PCNL, in patients with calcium-containing stones.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * age \> 18 years * stone free or had residual calcium oxalate stone fragments with a less than 4 mm. diameter at eight weeks after ESWL or PCNL Exclusion Criteria: * renal tubular obstruction * serum creatinine \> 2 mg/dl * urinary tract infection (bacteria \> 100,000 in urine culture) * hypersensitive or contraindication to Potassium sodium hydrogen citrate * insertion Double-J Stent * history of arrhythmia, myocardial infarction or digitalis administration

What they're measuring

rate of stone recurrence or stone growth

Timeframe: 12 months

Trial details

NCT IDNCT01329042

SponsorOuiheng International Healthcare Co., Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2007-10

View on ClinicalTrials.gov More Kidney Calculi trials